Phase II De-Escalation Study of Metronomic Decitabine/Cedazuridine Plus Venetoclax in AML

Phase II De-Escalation Study of Metronomic Decitabine/Cedazuridine Plus Venetoclax in AML
Conditions: Acute Myeloid Leukaemia (AML)

Interventions: Drug: Venetoclax, Decitabine/Cedaruridine; Drug: decitabine/cedazuridine

Sponsors: Rutgers, The State University of New Jersey

Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

October 11, 2026Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments